A Randomized, Double-Blind, Placebo-Controlled, Parallel, 4-Arm Dose Ranging Study of the Safety and Efficacy of Nalbuphine Extended-Release Tablets (NAL ER) for the Treatment of Cough in Idiopathic Pulmonary Fibrosis (IPF)
Latest Information Update: 17 Jun 2025
At a glance
- Drugs Nalbuphine (Primary)
- Indications Cough
- Focus Therapeutic Use
- Acronyms CORAL
- Sponsors Trevi Therapeutics
Most Recent Events
- 02 Jun 2025 Results presented in the Trevi Therapeutics Media Release.
- 01 Jun 2025 According to Trevi Therapeutics media release, announced a conference call and live webcast taking place tomorrow, Monday, June 2nd, 2025, at 8:30 a.m. ET, to share topline results from the Phase 2b CORAL trial of Haduvio in patients with IPF chronic cough.
- 18 Mar 2025 According to Trevi Therapeutics media release, the company announced positive outcome from sample size re-estimation in the Phase 2b CORAL trial, resulting in no change to study sample size, topline data expected in the second quarter of 2025